Toxic compounds such as carcinogens are removed from the body by the action of a series of detoxifying enzymes and transporters expressed in the liver and the small intestine. We have found that intestinal epithelial cells expressing the SV40 large T antigen (TAg) contain significantly lower levels of mRNAs, encoding several drug metabolizing/detoxifying enzymes and transporters compared to their non-transgenic littermates. In addition, TAg blocks the induction of these mRNAs by xenobiotics. The repression depends on an intact LXCXE motif in TAg, suggesting that inactivation of the retinoblastoma (Rb) family of tumor suppressors plays a role in the process. These results imply that a functional Rb pathway in the intestine is necessary for the expression of the detoxification system used to clear carcinogens, and suggest that loss of this tumor suppressor might alter susceptibility to chemical injury. In addition, the effect of TAg on the detoxification pathway appears to be tissuespecific, as its ectopic expression in the liver failed to suppress the P450 enzymes. The TAg-mediated suppression of drug metabolizing/detoxifying enzymes may have broad implications in the metabolism and mechanism of action of both carcinogens and prescription drugs.
Introduction
Simian virus 40 (SV40) encodes a dominantly acting oncoprotein, termed large T antigen (TAg). TAg transforms cells by binding key cellular targets and altering their activities (Ahuja et al., 2005) . In part, T antigenmediated transformation occurs through binding and inactivation of both the pRb family and the tumor suppressor p53. The retinoblastoma (Rb) family consists of three members: pRb, p107 and p130, which play both distinct and overlapping roles in governing exit from the cell cycle, differentiation and the maintenance of the quiescent state. Germline mutations that eliminate pRb function predispose the affected individuals to Rb and, thus, pRb is a tumor suppressor. In addition, the Rb gene is mutated in many types of sporadic cancers. The role of Rb proteins in regulating the cell cycle has been studied extensively. Much of this regulation is mediated through the interaction of Rb proteins with the E2F family of transcription factors. These studies indicate that loss of cell-cycle control is the principal way in which Rb inactivation contributes to tumorigenesis. However, recent studies suggest that pRb plays a role in maintaining genomic stability (Bosco et al., 2004; Mayhew et al., 2004) , therefore Rb inactivation might contribute to cancer by increasing the mutational rate.
We have previously used TAg to probe the role of pRb and p53 in the terminally differentiated adsorptive cells of the small intestine. Transgenic mice that express TAg in enterocytes reenter the cell cycle resulting in a uniform hyperplasia (Hauft et al., 1992) . In contrast, the enterocytes of mice expressing a mutant TAg that is unable to interact with Rb proteins are growth-arrested and the intestinal histology of these mice is normal (Chandrasekaran et al., 1996) . Expression of the first 121 or 136 amino acids of TAg, a region sufficient to inactivate Rb proteins, results in increased E2F activity, enterocyte proliferation and hyperplasia (Kim et al., 1994; Sa´enz Robles and Pipas, unpublished results) . Thus, the simplest hypothesis is that loss of Rb-protein function in enterocytes deregulates E2F activity resulting in cell-cycle entry. Proliferating enterocytes are still able to express the normal differentiation markers (Hauft et al., 1992) , indicating that transformation and differentiation are not mutually exclusive.
In addition to their role in nutrient absorption, enterocytes produce a number of proteins involved in drug metabolism and detoxification. Together with the liver, the intestine is one of the major organs responsible for removing toxins from the body, including carcinogens and drugs. The metabolism of toxins can be broadly classified into two phases: Phase I pathways usually involve oxidation processes, frequently hydroxylation or demethylation, and Phase II pathways involve conjugation to form more water-soluble products that are readily excreted from the body. The cytochrome P450 enzymes (CYPs) are responsible for the majority of Phase I pathways (Williams et al., 2004) , whereas glucuronosyltransferases , sulfotransferases and glutathione S-transferase (GST) account for most of the Phase II pathways. Drug transporters constitute another pathway by which drugs can be absorbed, distributed, or eliminated (Mizuno et al., 2003) . These include the efflux transporters, such as multidrug resistanceassociated protein 2 (MRP2), and uptake transporters, such as the organic anion transporting polypeptide (Kim, 2003; Kullak-Ublick, 2003) . Changes in the activity or polymorphic expression of drug metabolizing enzymes and transporters can affect the degree of absorption or elimination of drugs, thereby altering their therapeutic effects or toxicological response. These changes are manifested through inhibition, induction or genetic alterations of the enzyme or transporter. Viral infections have been reported in association with a compromised drug metabolizing/detoxification capacity (Renton, 2004) . However, it is not known whether the decreased detoxification results from the transcriptional repression of the enzymes and/or transporters.
During the course of analysing gene microarray studies on TAg transgenic tissues, we noticed that several members of the detoxification pathway were downregulated by TAg in enterocytes. Furthermore, the downregulation of GST by an N-terminal fragment of TAg has been reported previously (Sompayrac, 1997) . Thus, we undertook an investigation of the effects of TAg expression on the detoxification pathway.
Results

SV40 TAg downregulates multiple genes encoding detoxification proteins
We used Agilent cDNA microarrays to examine global patterns of gene expression in the small intestines of transgenic mice expressing TAg in enterocytes or in their non-transgenic (NT) littermates. Using a 1.4-fold ratio cutoff, T-antigen regulated 1396 genes (724 upregulated and 672 downregulated). We noted that among the genes downregulated by TAg expression were several members of the detoxification pathway (Supplementary Materials). TAg regulates 26 of the 128 detoxification genes present on the array (Table 1) : 22 are down and four are upregulated. Of the 40 P450 Phase I genes on the array, 14 (35%) of them were downregulated by TAg. The other class of genes most affected by TAg is the Phase II GST genes. Of the 14 GST phase II genes on the array, four (28%) of them were regulated by TAg. We verified that these 26 microarray clones aligned to their expected genes in the mouse genome by using BLAT at UCSC (http://genome.ucsc.edu). Of the 128 genes associated with the detoxification pathway, 26 of them are regulated by T antigen (22 down and 4 uregulated). The accession number and cloneID as supplied by Agilent are given. The name and symbol are based on NCBI Gene annotations. A positive fold change means that the gene is up regulated by T antigen expression. The P-value is based on a one-sample t-test. No P-value is given for genes where the degrees of freedom for the t-test is 0. Abbreviations: GST, glutathione S-transferase; MDR, multidrug resistant; MRP, multi-drug resistance protein; OAT, organic anion transporter; NHR, nuclear hormone receptor; NR, nuclear receptor.
TAg suppresses the constitutive expression of drug metabolizing enzymes and transporters in the intestine
We used Northern blot analysis to validate and extend the microarray analysis results. As shown in Figure 1 , the most notable change was a marked downregulation of CYP3A11 in the intestines of transgenic mice in both sexes. This enzyme, corresponding to human CYP3A4, is the most abundant P450 participating in the metabolism of 50-60% of clinical drugs (Maurel, 1996) . The expression of CYP2B10, another major P450 enzyme and homolog to human CYP2B6, was also decreased, whereas the expression of CYP2C29 remained largely unchanged. These results correlate with our initial microarray analysis, indicating a more pronounced downregulation of the CYP3A11 gene owing to TAg expression (À3.04, Table 1 ). The expression of the pregnane X receptor (PXR), known to be a positive regulator of CYP3A11 (Blumberg et al., 1998; Kliewer et al., 1998; Xie et al., 2000) , was unchanged in the transgenic mice ( Figure 1 ).
TAg blocks the xenobiotic-inducible expression of CYP3A11
The intestinal expression of CYP3A11 is induced by pregnenolone-16 a-carbonitrile (PCN), a synthetic antiglucocorticoid, and this induction is mediated by PXR (Xie et al., 2000) . We examined whether TAg also has impact on the xenobiotic-inducible expression of CYP3A11. As shown in Figure 2a , PCN treatment 24 h before killing induced intestinal CYP3A11 mRNA expression in the control mice as expected. The same drug, however, failed to induce CYP3A11 in the TAg transgenic intestines (Figure 2a ). The loss of inducibility depends on the transgene expression, as CYP3A11 induction in the liver, a tissue non-targeted by the transgene (Cohn et al., 1992; Hauft et al., 1992) , was intact ( Figure 2b ).
Repression of constitutive CYP3A11 expression requires TAg inactivation of Rb proteins
TAg is a multifunctional protein that regulates viral and cellular gene expression by several distinct mechanisms. To determine the activity linked to the xenobiotic detoxification pathway, we assessed the levels of CYP3A11 mRNA from the intestine of transgenic mice expressing two TAg mutants, TAg 3213 and TAg N136 ( Figure 3a) . We found that mutant TAg
3213
, which carries two amino acid substitutions (E107K and E108K) that render it unable to interact with Rb and other proteins (DeCaprio et al., 1988; Ewen et al., 1989; Srinivasan et al., 1997) , failed to repress the endogenous CYP3A11 mRNA levels (Figure 3b and c) . In contrast, TAg N136 , a truncation mutant that expresses the first 136 amino acids of TAg, and is sufficient to inactivate Rb proteins in vivo and in vitro, repressed the endogenous CYP3A11 mRNA expression with similar efficiency to TAg wt (Figure 3b and c). Interestingly, whereas the fulllength TAg was able to repress CYP3A11 induction in response to xenobiotics, both TAg 3213 and TAg N136 fail to repress that expression (Figure 3c ).
These results were confirmed and expanded by realtime-polymerase chain reaction (PCR) analysis with primers specific for murine CYP3A11 and CYP3A25, as well as Gstt1 and Mrp2 components of the Phase II and III response, respectively. Full-length TAg decreased both the endogenous and inducible mRNA levels of all four targets tested, corroborating the results from the microarray (Figure 4a ). In contrast, the TAg 3213 mutant was unable to decrease either the basal level or the inducible levels of CYP3A11 (Figure 4b ). Although TAg N136 repressed the basal levels of CYP3A11 mRNA to a similar extent as TAg wt , it was unable to block efficiently induction of CYP3A11 by PCN (Figure 4b) . Although different mutant mice show some differences in response (Figures 3b, c and 4b) , the overall pattern remained as described and was confirmed for other members of the P450 pathway (data not shown). These differences could be related to factors affecting drug absorption rates (e.g., different body fat content) or intrinsic factors related to the age and sex of the animals. We conclude that the TAg-mediated inactivation of Rb proteins is necessary for the repression of endogenous and inducible CYP3A transcripts in the intestine, and that additional functions mediated through the carboxy-terminal region of TAg are required for full repression of the response induced by PCN.
TAg is known to control cell transformation through different transcriptional activators and repressors. In particular, TAg interaction with the Rb proteins seems to release and activate E2F proteins, but the TAg 3213 mutant is unable to affect these complexes. Unlike TAg wt , TAg N136 is unable to bind and inactivate p53 or proteins associated with p53, such as CREB-binding protein (CBP) (Chrivia et al., 1993) . Nevertheless, the presence or absence of E2F, p53 or CREB-CBP-binding sites in promoters of the detoxification pathway genes did not correlate with their regulation by TAg, suggesting that these factors are unlikely to mediate directly the repression exerted by TAg (Supplementary Materials).
Hepatic expression of TAg does not inhibit CYP3A11 expression
The regulation of drug metabolizing enzymes in the intestine of transgenic mice prompted us to examine the effect of TAg on the expression of hepatic drug metabolizing enzymes. We used the hydrodynamics gene delivery system, injecting a large volume of DNA-containing solution, to target the expression of TAg to the liver (Liu et al., 1999) . NT mice were subjected to hydrodynamic delivery of the empty vector, TAg WT , VP-LXRa or VP-hPXR expressing vector. VPLXRa is a constitutively activated liver X receptor (LXR) alpha generated by fusing the VP16 activation domain of herpes simplex virus to the N-terminus of LXR. We have recently shown that the expression of VP-LXRa in the liver of transgenic mice downregulates the expression of CYP3A11 (Uppal and Xie, unpublished) . VP-hPXR is an activated form of hPXR that was generated with the same strategy and expression of VP-hPXR in transgenic mice results in sustained induction of CYP3A11 (Xie et al., 2000) . As expected, the hydrodynamic delivery of VP-LXRa and VP-hPXR resulted in the respective inhibition and induction of CYP3A11 ( Figure 5 ). In contrast to its effect in the intestine, a forced expression of TAg did not repress the expression of CYP3A11 in the liver ( Figure 5 ). Thus, TAg-mediated repression of CYP3A11 expression seems to be tissue-specific.
Discussion
Tumorigenic progression occurs through several mutational steps that drive normal cells toward full cancer. Multiple genetic and environmental factors contribute to and alter this progression through different methods, one of the most relevant being the loss of genetic stability, which potentially increases the mutation frequency. Exogenous chemicals and toxic metabolic intermediates can also increase the rate of mutation. To guard against this, organisms have developed a defense mechanism to detoxify compounds that exert toxicity or carcinogenicity. The cytochrome P450 enzymes (CYPs) catalyze the oxidative metabolism of a vast array of hydrophobic chemicals, including both therapeutic drugs and toxic components. Mutations in cytochrome P450 genes or deficiencies of the enzymes are responsible for several human diseases. Foreign chemicals or drugs are also called xenobiotics, and their metabolism takes place in two phases: Phase I is carried out by CYPs that add a functional group (i.e., hydroxyl) that can be used to attach a conjugate. Although the resulting metabolic intermediates from Phase I often exert toxicity or carcinogenicity, they are targets for Phase II enzymedependent conjugation, which transforms them into more water-soluble, inactive polar products suitable for excretion in the urine. As a result, many different cytotoxic drugs are inactivated by the action of CYPs. However, these compounds can also be activated, thus rendering them cytotoxic or carcinogenic. These mechanisms put the P450 enzymes in a unique position to play an important role both in the etiology of cancer and as determinants of cancer therapy (Oyama et al., 2004; Rooseboom et al., 2004) . Therefore, the P450 cytochromes have been extensively studied in regard to their possible role in cancer progression and treatment (reviewed by McFadyen et al., 2001; Rodriguez-Antona and Ingelman-Sundberg, 2006) . The P450 genes are constitutively expressed in tissues such as the liver and intestine, to ensure a fast response to environmental injuries. Their levels are upregulated by exposure to xenobiotics (Xie et al., 2004) . In particular, the CYP3A subfamily is the most important drug metabolizing family in humans and mice and the most abundant P450 in the liver. We have found that the expression of SV40 large TAg in the intestine leads to a repression of mRNA levels encoding several members of this detoxification system, particularly several members of the CYP3A family. The failure to see a similar effect in the liver after hydrodynamic delivery of TAg ( Figure 5 ) might be related to the short term expression of the oncogene under these conditions (8 h) in comparison with the continuous expression achieved in the intestine of transgenic mice, or it could be the result of cell-specific requirements not addressed in this study. The CYP3A family is responsible for the metabolism of over 120 different drugs, from pain relievers and narcotics (acetominophen, codeine) to antibiotics and cancer drugs (erythromycin, Taxol) (http://drnelson. utmem.edu/cytochromeP450.html). In addition to its ability to repress the basal levels of intestinal P450s, TAg is also able to repress the induction of P450 mRNAs in response to xenobiotic inducers, such as PCN. Viral infections are known to be associated with a compromised drug metabolizing/detoxification capacity (Renton, 2004) . Our results suggest a plausible mechanism through transcriptional repression of the P450 pathway. The specific mechanisms by which TAg alters the detoxification pathway remain to be elucidated. One potential mechanism is that TAg suppresses the expression and/or activity of positive regulators of these enzymes and transporters. However, the expression of PXR, a positive regulator of drug metabolizing enzymes and transporters (reviewed by Xie et al., 2004) , was unaffected by TAg (Figure 1a) . Similarly, cotransfection of TAg does not affect PXR activity in transient transfections and luciferase reporter gene assays (data not shown), indicating that a functional interplay between TAg and PXR is unlikely. Nevertheless, regulation of the pathway through other positive regulators of the CYP family cannot be excluded.
The ability of TAg to repress the constitutive expression and the drug induction of genes encoding detoxification proteins depends on an intact LXCXE motif, and suggests that TAg-dependent inactivation of the Rb family of tumor suppressors plays a role in this regulation. This has important implications for tumor progression and cancer therapy. It is possible that the loss of pRb protein additionally increases a tumor susceptibility to carcinogens, thus further contributing to tumor progression. In addition, the metabolism of anticancer drugs is likely to be altered in the absence of a functional pRb product. Both TAg N136 and TAg 3213 fail to block CYP induction by PCN. Thus, although the LXCXE motif is sufficient to regulate endogenous CYP levels, both pRb inactivation and some unidentified activity in the C-terminal region of TAg are required to block induction of the system by xenobiotics.
We speculate that one possible consequence of Rb inactivation in intestine is the loss of key components of the detoxification system. In fact, previous reports indicated that SV40 TAg is able to downregulate the endogenous expression of GSTa in cultured cells, rendering them more sensitive to alkylating drugs (Sompayrac, 1997) . However, in contrast to our results, such downregulation did not require the formation of a complex between large TAg and either p53, CBP/p300, or the pRb family of proteins (Sompayrac, 1997) . It is possible that TAg exerts its control over the detoxification pathway through different mechanisms, and not all of them are mediated through the same cellular components. On the other hand, the intestinal cells used in this study still possess the capacity to trigger the detoxification pathway in response to chemical stimuli (e.g., PCN), a property lost in established cells maintained in cell culture. It is likely that maintenance of cellular pathways, including their response to chemical assault, is achieved by different methods in different cell types.
Many of drug metabolizing enzymes and transporters are involved in the biotransformation and homeostasis of endogenous and exogenous chemicals that influence multiple physiological and pathological processes in mammals, but few reports earlier to this study have suggested a link between the genetic status of Rb and the detoxification pathways (for a review, see Puga et al., 2002) . The TAg-mediated regulation of these proteins may have a broad physiological impact. As members of the pathways that control drug metabolism and toxin clearance in response to both beneficial drugs and carcinogens, our studies reinforce the concept that inactivation of the Rb family of tumor suppressors could alter both susceptibility to carcinogens and to anticancer therapeutics. We are currently testing this hypothesis using gene knockout models. ). TAg wt mice were obtained from Jeff Gordon (Washington University) and have been described (Hauft et al., 1992; Kim et al., 1993) . TAg N136 and TAg 3213 mice have been generated in our laboratory and will be described elsewhere (Sa´enz Robles et al., in preparation) . In addition to TAg, all transgenic constructs allow for the expression of SV40 small t. All pedigrees were maintained by crosses to NT FVB mice. The genotype of each mouse was determined using the PCR with DNA from murine tails and DNA primers complementary to regions in the IFABP promoter and 3 0 -end of the SV40 TAg wt intron (Sa´enz Robles et al., in preparation).
Materials and methods
Maintenance of transgenic mice
Tissue preparation and RNA isolation Mice were killed and their small intestines were removed, dissected longitudinally and washed in saline solution.
Portions of the liver were also collected. All materials were either used immediately or frozen in liquid nitrogen until processed. Total RNA was extracted using the Trizol reagent (Invitrogen, Carlsbad, CA, USA).
Microarray
Total RNA was extracted from the middle sections of whole small intestines of four TAg transgenic mice and four NT littermates. A detailed protocol will be described elsewhere (Cantalupo et al., in preparation) . Briefly, total RNA from the small intestine of four T-antigen transgenic and four NT mice was converted into complementary DNA (cDNA) by reverse transcription and directly labeled with Cy3-dUTP and Cy5-dUTP, in independent reactions. For each TAg and NT littermate pair, their labeled cDNAs were mixed together in dye-flip design (Cy5-T þ mixed with Cy3-NT cDNA and Cy3-T þ mixed with Cy5-NT cDNA). Each labeled cDNA mixture of the dye-flip pair was applied to a separate array and analysed at the same time. After averaging technical replicate (dye-flip) ratios, we obtained a maximum of four biological replicate ratios for each gene.
Northern blot analysis
Northern blot analysis was performed as described previously (Xie et al., 2000) and the membranes were hybridized with 32 P-labeled cDNA probes. The probes for CYP3A11 and CYP2B10 were described previously (Xie et al., 2000; Saini et al., 2005; Uppal et al., 2005) . When necessary, quantification was performed with the NIH Image software and the relative expression of different RNAs is presented after normalization against the control glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Drug treatment
An intraperitoneal injection of either the control solvent dimethyl sulphoxide (DMSO) or PCN (final dose 40 mg/kg) was administered to mice 24 h before killing. The intestines and livers were harvested and processed for RNA extraction as described above.
Real-time PCR analysis
Total RNA from murine tissues was extracted using the RNeasy kit (Qiagen, Valencia, CA, USA). one microgram of RNA was reverse-transcribed into cDNA using the Superscript First-Strand Synthesis kit (Invitrogen). The cDNAs were amplified with an Applied Biosystems 7300 cycler, using the default conditions suggested by the manufacturer and primers specific for CYP3A11 (5 0 -GGAAAGCCGCCTGGATTCT AAG/5 0 -ATGCTGCCCTTGTTCTCCTTGC), CYP3A25 (5 0 -CCGTTACTTGGCACCATTTT/5 0 -GTCTTTCATGCTGAT GGGCT), Gstt1 (5 0 -TGTGTGAGAGTGTGGCTATCTTGC/ 5 0 -TTATGATGAGGTCAGCAGGGGGAC), Mrp2 (5 0 -ACGG TCATCACTATCGCACACAGG/5 0 -TTGCTTGAGCCTTAG AGTTTGAGG) and ribosomal protein (Rpl5) (5 0 -CCAA ACGATTCCCTGGTAATGAC/5 0 -GACGATTCCACCTCT TCTTCTTCAC).
Hydrodynamic liver transfection
Each plasmid DNA (5 mg) was dissolved in 1.5 ml of phosphate-buffered saline and injected in less than 10 s into a 18-20 g mouse via its tail vein, as described previously (Liu et al., 1999) . Mice were killed 8 h after transfection and their tissues were harvested for analysis. All expression vectors were constructed with the Cytomegalovirus promoter-based pCMX vector (Xie et al., 2000) . The constitutively activated VP-LXRa and VP-hPXR were generated by fusing the VP16 activation domain of herpes simplex virus to the N-terminus of LXRa and hPXR, respectively.
